Related Experiment Videos

[Does targeted therapy of type 2 diabetes prevent cardiovascular incidents?]

Matthias Leschke1

  • 1Klinik für Kardiologie, Städtische Kliniken Esslingen. m.leschke@kliniken-es.de

Medizinische Klinik (Munich, Germany : 1983)
|December 26, 2003
PubMed

Insights

Acarbose significantly reduces cardiovascular risk in patients with impaired glucose tolerance or non-insulin-dependent diabetes mellitus. This finding challenges the "glucose paradox" and offers new therapeutic options for metabolic syndrome.

Area of Science:

  • Endocrinology
  • Cardiology
  • Pharmacology

Context:

  • Rising prevalence of non-insulin-dependent diabetes mellitus (NIDDM), metabolic syndrome, and impaired glucose tolerance.
  • Established link between impaired glucose tolerance and increased cardiovascular risk.
  • Limited success of intensified diabetes therapy in reducing macrovascular complications, leading to the "glucose paradox" concept.

Purpose:

  • To evaluate the efficacy of acarbose in reducing cardiovascular events in patients with impaired glucose tolerance and NIDDM.
  • To investigate therapeutic options for managing cardiovascular risk in metabolic disorders.

Summary:

  • The STOP-NIDDM study demonstrated a 49% reduction in cardiovascular events with acarbose in impaired glucose tolerance patients versus placebo.
  • A meta-analysis of seven long-term studies showed a 41% reduction in cardiovascular events with acarbose in NIDDM patients.
  • Acarbose effectively mitigates cardiovascular risk in individuals with impaired glucose tolerance and NIDDM.

Impact:

  • Provides strong evidence for acarbose as a cardiovascular risk-reducing agent in prediabetes and NIDDM.
  • Offers a viable therapeutic strategy to address the "glucose paradox" and improve patient outcomes.
  • Highlights the importance of early intervention in managing metabolic syndrome and associated cardiovascular complications.

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...